Because our in vitro results suggested that ANT2 knockdown enhances the apoptosis-inducing potential of TRAIL in MCF7 cells in vitro, we next examined the effects of ANT2 shRNA/TRAIL combination therapy on a breast cancer xenograft model in vivo. This evidence concerns the gene TNFSF10 and breast carcinoma.